The dosimetric quality of brachytherapy implants in patients with small prostate volume depends on the experience of the brachytherapy team

Liu, Hongwei; Malkoske, Kyle; Sasaki, David; Bews, J.; Demers, Alain; Nugent, Zoann; Ong, Aldrich; Bashir, Bashir; Dufan, Tarek A.; Cho, Patrick; Drachenberg, Darryl; Chowdhury, Anirban

doi:10.1016/j.brachy.2009.07.009

Cited by 31 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with reports from prostate cancer brachytherapy [21][22][23][24] 3 ) may be found in the increasing systematic use of interstitial needles and more advanced dose optimization techniques [25,26]. Further dose escalation for the CTV HR and dose constraints for OARs could be established only after some years of experience.…”

Section: Discussionsupporting

confidence: 71%

Evaluation of planning aims and dose prescription in image-guided adaptive brachytherapy and radiochemotherapy for cervical cancer: Vienna clinical experience in 225 patients from 1998 to 2008

et al. 2015

View full text Add to dashboard Cite

Results . In the PA ϩ group there were 77 (34%) and in the PA-group 148 (66%) patients. In the PA-group, CTV HR D 90 Ͻ 85 Gy was prescribed in 82 patients, D 2cm3 bladder Ͼ 90 Gy was prescribed in 80 patients and D 2cm3 Rectum Ͼ 70 Gy in 60 patients. Fulfi llment of the PA for dose prescription improved from 4% in the learning period to 48% in the protocol period. The fi ve-year event-free interval was 64% in the learning period and 84% in the protocol period (p ϭ 0.008). Conclusion . Fulfi llment of all PAs for dose prescription is challenging -especially in patients with more advanced tumors. However, with growing experience fulfi llment of PA for dose prescription can be signifi cantly increased (learning and protocol period). Such increase in fulfi lling PA for dose prescription is followed by a signifi cant improvement in clinical outcome.The gold standard in the treatment of locally advanced cervix cancer is radio-chemotherapy and brachytherapy [1]. Image-guided adaptive brachytherapy (IGABT) is an advanced method which is increasingly implemented in clinical practice [2,3]. By imaging of the applicator and tumor/target volume and the surrounding organs at risk (OAR), IGABT offers the possibility of dose optimization based on the individual high risk (HR) clinical target volumes (CTV) and OARs [4 -7]. First clinical results indicate a reduction in local recurrence and side effects in comparison to standard point A based brachytherapy [8 -11]. Recently, dose response relationships were described in IGABT for the target volume and OARs (bladder and rectum) based on the monoinstitutional Vienna cohort and also based on the large multi-center cohort RetroEMBRACE [12 -15].

show abstract

Section: Discussionsupporting

confidence: 71%

Evaluation of planning aims and dose prescription in image-guided adaptive brachytherapy and radiochemotherapy for cervical cancer: Vienna clinical experience in 225 patients from 1998 to 2008

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Acquisition of skills, advancement of knowledge over time as well as clinical experience acquired with more number of cases can affect the ultimate outcome of the patients, and this has been proven by Le Fur et al [20] and Liu et al [21] in their studies on brachytherapy implants for prostate cancers. Hence, it is important to infuse the interest of brachytherapy in the beginning of the radiation oncology teaching programme.…”

Section: Discussionmentioning

confidence: 99%

Attitude and Practice of Brachytherapy in India: A Study Based on the Survey Amongst Attendees of Annual Meeting of Indian Brachytherapy Society

et al. 2015

View full text Add to dashboard Cite

“…However, it has also been demonstrated that outcomes after BT are highly operatordependent [86,87] and the published data from expert BT centers that deliver the highestquality implants may overestimate the effectiveness of BT in many real-world settings. Observational data capturing BT versus other treatment options are limited, however, and details of BT quality indicators are not available in large registries such as the SEER database.…”

Section: Ebrt Versus Btmentioning

confidence: 96%

Comparative Effectiveness Research for Prostate Cancer Radiation Therapy: Current Status and Future Directions

et al. 2011

View full text Add to dashboard Cite

Comparative effectiveness research aims to help clinicians, patients and policymakers make informed treatment decisions under real-world conditions. Prostate cancer patients have multiple treatment options, including active surveillance, androgen deprivation therapy, surgery and multiple modalities of radiation therapy. Technological innovations in radiation therapy for prostate cancer have been rapidly adopted into clinical practice despite relatively limited evidence for effectiveness showing the benefit for one modality over another. Comparative effectiveness research has become an essential component of prostate cancer research to help define the benefits, risks and effectiveness of the different radiation therapy modalities currently in use for prostate cancer treatment.

show abstract

The dosimetric quality of brachytherapy implants in patients with small prostate volume depends on the experience of the brachytherapy team

Cited by 31 publications

References 23 publications

Evaluation of planning aims and dose prescription in image-guided adaptive brachytherapy and radiochemotherapy for cervical cancer: Vienna clinical experience in 225 patients from 1998 to 2008

Evaluation of planning aims and dose prescription in image-guided adaptive brachytherapy and radiochemotherapy for cervical cancer: Vienna clinical experience in 225 patients from 1998 to 2008

Attitude and Practice of Brachytherapy in India: A Study Based on the Survey Amongst Attendees of Annual Meeting of Indian Brachytherapy Society

Comparative Effectiveness Research for Prostate Cancer Radiation Therapy: Current Status and Future Directions

Contact Info

Product

Resources

About